Clinical trials: Hematological Neoplasm
Hematological Malignancies
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 [Dose Escalation]) and to further…
- Trial name
- MonumenTAL-1 (NCT03399799)
- Testing
- Talquetamab
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 279 people
- Sponsor
- Janssen Research & Development, LLC
Polycythemia Vera
A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera
This clinical trial is a Phase 2/3 study that will determine the recommended dose and dose regimen of AG-236 and evaluate the efficacy, safety, and pharmacokinetics of AG-236 in polycythemia vera (PV) by testing how well AG-236…
- Trial name
- PreVail (NCT07859423)
- Testing
- AG-236
- Volunteers
- 245 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Advanced Solid Tumors, Hematologic Malignancies
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate hepatic impairement or severe hepatic…
- Trial name
- NCT01912222
- Testing
- IXAZOMIB
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer, Solid Tumor
Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
This is an investigator-initiated trial aimed at evaluating the safety and preliminary efficacy of a novel red blood cell-based therapy, where engineered red blood cells are conjugated with checkpoint inhibitors.
- Conditions
- Cancer, Solid Tumor, Hematologic Malignancy
- Trial name
- Reboot-101 (NCT05707325)
- Testing
- engineered red blood cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Westlake Therapeutics
Polycythemia Vera
A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France
The aim of this study was to assess which cytoreductive treatments are currently administered in standard practice as second-line therapy to patients with polycythemia vera (PV) in France and to find out the reasons physicians…
- Trial name
- VeRavie (NCT07839858)
- Where
- 51 sites in France
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Hematological Malignancies
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of oral nemtabrutinib in Chinese participants at least 18 years of age who have Relapsed/Refractory hematologic malignancies.
- Trial name
- NCT05347225
- Testing
- Nemtabrutinib
- Where
- 5 sites in China
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Malignancies, Multiple Myeloma
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma
This is an open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult patients with lymphoma or multiple myeloma.
- Conditions
- Hematologic Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT00722488
- Testing
- MLN4924
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Myelodysplastic Syndromes, Leukemia Myeloid Acute
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
This is a post-authorization, retrospective multicentre observational nationwide study (PAS-OD). It will be conducted by reviewing medical records and database of patients who participated in the validation of the psychometric…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell
- Trial name
- NCT02842229
- Where
- 15 sites in Spain
- Volunteers
- 117 people
- Sponsor
- Celgene
Polycythemia Vera
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
- Trial name
- NCT00595829
- Testing
- XL019
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Exelixis
Hematological Malignancies
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell…
- Trial name
- NCT04959903
- Testing
- Allogeneic T cell progenitors, cultured ex-vivo
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Smart Immune SAS
Advanced Solid Tumors or Hematologic Malignancies
Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology
The retrospective cohort study INFINITY will be an instrument to analyze the current practice of precision oncology in the real-world setting.
- Trial name
- INFINITY (NCT04389541)
- Where
- 97 sites in Germany
- Volunteers
- 499 people
- Sponsor
- iOMEDICO AG
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid…
- Trial name
- ABC123 (NCT03203369)
- Testing
- UCART123
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cellectis S.A.
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM)
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
The study is designed to evaluate safety, immunogenicity, and preliminary anti-tumor activity of a multi-peptide immunotherapy (BB-MPI-03) at three peptide+adjuvant dose levels.
- Conditions
- Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
- Trial name
- BBMPI03 (NCT02240537)
- Testing
- Sargramostim, BB-MPI-03, Montanide
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Benovus Bio, Inc.
Advanced Solid Tumor, Hematological Malignancy
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
- Trial name
- NCT06225856
- Testing
- YY201
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Yuyao Biotech Co., Ltd.
Polycythemia Vera (PV), Myelofibrosis (MF)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and…
- Conditions
- Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
- Trial name
- NCT07469891
- Testing
- PRT12396
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Prelude Therapeutics Incorporated
Advanced Tumors
Study of BMS-986158 in Subjects With Select Advanced Cancers
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
- Trial name
- BET (NCT02419417)
- Testing
- BMS-986158, Nivolumab
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
Neoplasm
Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
This is an open label expanded access protocol for the treatment of up to approximately 40 adult or pediatric (defined as age <18 years) patients with tumors harboring either a chromosomal translocation or activating mutation…
- Trial name
- NCT02473497
- Testing
- Crizotinib
- Where
- 17 sites in United States
- Sponsor
- Pfizer
Hematologic Neoplasms
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.
- Trial name
- NCT02367196
- Testing
- CC-90002, Rituximab
- Where
- 13 sites in United States, Spain
- Volunteers
- 60 people
- Sponsor
- Celgene
Hematologic Malignancy, Leukemia
Better Leukemia Diagnostics Through AI (BELUGA)
To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms.
- Conditions
- Hematologic Malignancy, Leukemia, Minimal Residual Disease, Lymphoma
- Trial name
- BELUGA (NCT04466059)
- Testing
- Automated AI-Guided Diagnosis of Hematological Malignancies
- Where
- Germany
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Munich Leukemia Laboratory
Refractory Leukemia, Acute Myelogenous Leukemia
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.
- Trial name
- NCT00880269
- Testing
- Panobinostat/LBH589
- Where
- 40 sites in United States, Australia and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals